Uitkomsten in de dagelijkse praktijk van eerstelijnschemotherapie voor niet-resectabel stadium III en IV urotheelcarcinoom van de blaas

Santeon MIBC-studiegroep; Daan J. Reesink; Ewoudt M.W. van de Garde; Paul B. van der Nat; Maartje Los; Simon Horenblas; Harm H.E. van Melick

doi:10.1007/s13629-024-00425-5

Uitkomsten in de dagelijkse praktijk van eerstelijnschemotherapie voor niet-resectabel stadium III en IV urotheelcarcinoom van de blaas

Translated title of the contribution: Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer

Santeon MIBC-studiegroep, Daan J. Reesink^*, Ewoudt M.W. van de Garde, Paul B. van der Nat, Maartje Los, Simon Horenblas, Harm H.E. van Melick

^*Corresponding author for this work

Research output: Contribution to journal › Article › Professional

Abstract

The aim of this study was to evaluate the disparity between the efficacy observed in clinical trials and effectiveness in real-world practice (efficacy-effectiveness gap (EE gap)) in palliative first-line (1L) chemotherapy treatment (CTx) for urothelial carcinoma of the bladder. From seven Dutch teaching hospitals, all patients diagnosed with unresectable stage III (cT2-4aN1-3M0) and IV (cT4b and/or cM1) disease, who received 1L-CTx between 2008 and 2016, were captured. Median overall survival (mOS) of gemcitabine + cisplatin (GemCis)-patients was 10.4 months (95%-CI 7.9–13.0), which was shorter compared to clinical trial findings (range mOS: 12.7–14.3 months) despite comparable clinical characteristics. An EE gap seems present. The mOS of gemcitabine + carboplatin (GemCarbo)-patients was 9.3 months (95%-CI 7.5–11.1). GemCarbo patients had worse prognostic characteristics (higher age, impaired renal function and worse performance status (all p-values < 0.001)) compared to GemCis patients, but survival was not statistically significant different in a multivariable regression analysis (HR 0.90 (95%-CI 0.55–1.47), p-value = 0.674).

Translated title of the contribution	Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer
Original language	Dutch
Pages (from-to)	74-84
Number of pages	11
Journal	Tijdschrift voor Urologie
Volume	14
Issue number	4
DOIs	https://doi.org/10.1007/s13629-024-00425-5
Publication status	Published - Jul 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2024.

Keywords

Bladder cancer
Efficacy-effectiveness gap
First-line chemotherapy
Metastatic
Real-world outcomes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s13629-024-00425-5Licence: CC BY

s13629-024-00425-5Final published version, 1,000 KBLicence: CC BY

Cite this

@article{40518195c5134a4cae637d5d12102648,

title = "Uitkomsten in de dagelijkse praktijk van eerstelijnschemotherapie voor niet-resectabel stadium III en IV urotheelcarcinoom van de blaas",

abstract = "The aim of this study was to evaluate the disparity between the efficacy observed in clinical trials and effectiveness in real-world practice (efficacy-effectiveness gap (EE gap)) in palliative first-line (1L) chemotherapy treatment (CTx) for urothelial carcinoma of the bladder. From seven Dutch teaching hospitals, all patients diagnosed with unresectable stage III (cT2-4aN1-3M0) and IV (cT4b and/or cM1) disease, who received 1L-CTx between 2008 and 2016, were captured. Median overall survival (mOS) of gemcitabine + cisplatin (GemCis)-patients was 10.4 months (95\%-CI 7.9–13.0), which was shorter compared to clinical trial findings (range mOS: 12.7–14.3 months) despite comparable clinical characteristics. An EE gap seems present. The mOS of gemcitabine + carboplatin (GemCarbo)-patients was 9.3 months (95\%-CI 7.5–11.1). GemCarbo patients had worse prognostic characteristics (higher age, impaired renal function and worse performance status (all p-values < 0.001)) compared to GemCis patients, but survival was not statistically significant different in a multivariable regression analysis (HR 0.90 (95\%-CI 0.55–1.47), p-value = 0.674).",

keywords = "Bladder cancer, Efficacy-effectiveness gap, First-line chemotherapy, Metastatic, Real-world outcomes",

author = "\{Santeon MIBC-studiegroep\} and Reesink, \{Daan J.\} and \{van de Garde\}, \{Ewoudt M.W.\} and \{van der Nat\}, \{Paul B.\} and Maartje Los and Simon Horenblas and \{van Melick\}, \{Harm H.E.\} and Biesma, \{D. H.\} and Stijns, \{P. E.F.\} and J. Lavalaye and \{de Bruin\}, \{P. C.\} and Peters, \{B. J.M.\} and Somford, \{D. M.\} and M. Berends and R. Richardson and \{Van Andel\}, G. and Klaver, \{O. S.\} and Haberkorn, \{B. C.M.\} and \{Van Rooijen\}, \{J. M.\} and Korthorst, \{R. A.\} and Meijer, \{R. P.\} and \{Van der Voort Van Zyp\}, \{J. R.N.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = jul,

doi = "10.1007/s13629-024-00425-5",

language = "Dutch",

volume = "14",

pages = "74--84",

journal = "Tijdschrift voor Urologie",

issn = "2211-3037",

publisher = "Springer Science + Business Media",

number = "4",

}

TY - JOUR

T1 - Uitkomsten in de dagelijkse praktijk van eerstelijnschemotherapie voor niet-resectabel stadium III en IV urotheelcarcinoom van de blaas

AU - Santeon MIBC-studiegroep

AU - Reesink, Daan J.

AU - van de Garde, Ewoudt M.W.

AU - van der Nat, Paul B.

AU - Los, Maartje

AU - Horenblas, Simon

AU - van Melick, Harm H.E.

AU - Biesma, D. H.

AU - Stijns, P. E.F.

AU - Lavalaye, J.

AU - de Bruin, P. C.

AU - Peters, B. J.M.

AU - Somford, D. M.

AU - Berends, M.

AU - Richardson, R.

AU - Van Andel, G.

AU - Klaver, O. S.

AU - Haberkorn, B. C.M.

AU - Van Rooijen, J. M.

AU - Korthorst, R. A.

AU - Meijer, R. P.

AU - Van der Voort Van Zyp, J. R.N.

PY - 2024/7

Y1 - 2024/7

N2 - The aim of this study was to evaluate the disparity between the efficacy observed in clinical trials and effectiveness in real-world practice (efficacy-effectiveness gap (EE gap)) in palliative first-line (1L) chemotherapy treatment (CTx) for urothelial carcinoma of the bladder. From seven Dutch teaching hospitals, all patients diagnosed with unresectable stage III (cT2-4aN1-3M0) and IV (cT4b and/or cM1) disease, who received 1L-CTx between 2008 and 2016, were captured. Median overall survival (mOS) of gemcitabine + cisplatin (GemCis)-patients was 10.4 months (95%-CI 7.9–13.0), which was shorter compared to clinical trial findings (range mOS: 12.7–14.3 months) despite comparable clinical characteristics. An EE gap seems present. The mOS of gemcitabine + carboplatin (GemCarbo)-patients was 9.3 months (95%-CI 7.5–11.1). GemCarbo patients had worse prognostic characteristics (higher age, impaired renal function and worse performance status (all p-values < 0.001)) compared to GemCis patients, but survival was not statistically significant different in a multivariable regression analysis (HR 0.90 (95%-CI 0.55–1.47), p-value = 0.674).

AB - The aim of this study was to evaluate the disparity between the efficacy observed in clinical trials and effectiveness in real-world practice (efficacy-effectiveness gap (EE gap)) in palliative first-line (1L) chemotherapy treatment (CTx) for urothelial carcinoma of the bladder. From seven Dutch teaching hospitals, all patients diagnosed with unresectable stage III (cT2-4aN1-3M0) and IV (cT4b and/or cM1) disease, who received 1L-CTx between 2008 and 2016, were captured. Median overall survival (mOS) of gemcitabine + cisplatin (GemCis)-patients was 10.4 months (95%-CI 7.9–13.0), which was shorter compared to clinical trial findings (range mOS: 12.7–14.3 months) despite comparable clinical characteristics. An EE gap seems present. The mOS of gemcitabine + carboplatin (GemCarbo)-patients was 9.3 months (95%-CI 7.5–11.1). GemCarbo patients had worse prognostic characteristics (higher age, impaired renal function and worse performance status (all p-values < 0.001)) compared to GemCis patients, but survival was not statistically significant different in a multivariable regression analysis (HR 0.90 (95%-CI 0.55–1.47), p-value = 0.674).

KW - Bladder cancer

KW - Efficacy-effectiveness gap

KW - First-line chemotherapy

KW - Metastatic

KW - Real-world outcomes

UR - https://www.scopus.com/pages/publications/85187155797

U2 - 10.1007/s13629-024-00425-5

DO - 10.1007/s13629-024-00425-5

M3 - Article

AN - SCOPUS:85187155797

SN - 2211-3037

VL - 14

SP - 74

EP - 84

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

IS - 4

ER -